CORAL GABLES, FL/ ACCESSWIRE / March 19, 2019 / In the last few months, the healthcare stock market has responded favorably to the fact that the healthcare industry is one of the fastest changing sectors in the global marketplace. Naturally, over time, the global population has increased in both number and age, with the older members of the populous representing a group of individuals in dire of need of qualitative healthcare. Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Although the healthcare sector is still growing, if companies continue as they have been, the future looks promising. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday.
Premier Health Group (PHGRF) (PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.
Premier Health Group (PHGRF) (PHGI) dominated headlines this month when the Company announced that it would start working with Bio Conscious Technologies to bring their artificial intelligence technology to Premier Health's active patient network. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (PHGRF) (PHGI), commented, "since the beginning, remote patient monitoring has been an integral component of our telemedicine app. DiaBits will enable our diabetic patients to dramatically increase glucose control and improve their quality of life. We are eager to work with the team at BCT to bring this innovative solution to our comprehensive telemedicine app."
Vaxart Inc (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, saw its shares enjoy a 54.54% boost in Tuesday's trading, with its shares trading at $2.58 per share early in the afternoon. The Company today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart's common stock, at a purchase price of $2.50 per share, for aggregate gross proceeds of $3 million.
Per the details of the announcement, the offering is expected to close on or about March 20, 2019, subject to the satisfaction of customary closing conditions.
BioPharmX Corporation (BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, last week reported financial results for the quarter and year ended January 31, 2019. Per their reported results, the Company initiated and completed enrollment for its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
Dr. Tierney, CEO of BioPharmX, said, "we met our primary objectives this quarter in completing the enrollment of our BPX-04 Phase 2b clinical trial, bolstering our board of directors and reducing our operating costs. The company has and will continue to make the necessary changes to position the company for long-term success and we look forward to informing our shareholders as we make further progress."
Trevena Inc (TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, last week reported its financial results for the fourth quarter and full year ended December 31, 2018, and provided an overview of its 2018 and 2019 year-to-date operational highlights.
Per the details of their results, the Company completed a Phase 1 trial for TRV250, a potential new mechanism of action for the treatment of acute migraine and commenced a partnership with the National Institute on Drug Abuse (NIDA) for TRV734 in the management of opioid use disorder. In its S1P receptor program, the Company is today announcing its identification of a lead candidate for this program, designated as TRV045. This candidate holds promise as a new mechanism of action for a novel, non-opioid treatment of chronic pain and other CNS conditions.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: